Compare ITI Pharma and Healthcare Fund vs HDFC Pharma And Healthcare Fund
ITI Pharma and Healthcare Fund
EquitySectoral-Pharma
HDFC Pharma And Healthcare Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.57
2.12
NAV
₹19.87
₹22.48
Fund Started
18 Oct 2021
14 Sep 2023
Fund Size
₹266.05 Cr
₹3501.37 Cr
Exit Load
Exit load of 0.50%, if redeemed within 3 months.
Exit load of 1%, if redeemed within 30 days.
1 Year
9.54%
24.10%
3 Year
18.45%
29.48%
5 Year
-
-
Equity
99.31%
96.77%
Cash
0.69%
3.23%
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.96% |
Divi's Laboratories Ltd. | 9.51% |
Apollo Hospitals Enterprise Ltd. | 5.45% |
Dr. Reddy's Laboratories Ltd. | 4.78% |
Torrent Pharmaceuticals Ltd. | 4.78% |
Max Healthcare Institute Ltd. | 4.49% |
Cipla Ltd. | 4.19% |
Laurus Labs Ltd. | 4.02% |
Aurobindo Pharma Ltd. | 4.01% |
Mankind Pharma Ltd. | 3.78% |
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 9.39% |
Sun Pharmaceutical Industries Ltd. | 8.28% |
Alkem Laboratories Ltd. | 4.64% |
Cipla Ltd. | 4.15% |
Apollo Hospitals Enterprise Ltd. | 3.69% |
Torrent Pharmaceuticals Ltd. | 3.65% |
Max Healthcare Institute Ltd. | 3.61% |
Aster DM Quality Care Ltd. | 3.56% |
Lupin Ltd. | 3.55% |
Neuland Laboratories Ltd. | 3.24% |
Name
-
-
Start Date
-
-
Description
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Launch Date
18 Oct 2021
14 Sep 2023
